




1H23: strong growth in Fee Income (+30%), results broadly in line with expectations

**Sector: Finance** 

Sound growth driven by asset management and advisory. SCM Sim just released a healthY set of 1H23 results which were largely in line with our expectations. Fee income stood at Euro 3.6, +42% YoY mainly driven by advisory services (Euro 2.7 m vs Euro 0.7 m in 1H22) and asset management (+16%) whereas the insurance line saw a contraction (-60%) following the crisis of life insurer Eurovita which affected the entire Italian industry in the first six month of the year. Performance fees remained very limited (Euro 77 k in 1H22) in line with last year (Euro 0.0 m). Brokerage Margin stood at Euro 1.9 m, vs. Euro 1.5 m recoded in 1H2, +31% following the increase in fee income and partially offset by lower Brokerage Margin/Fee income which stood at 53%, down vs. 1H2 (58%). The decrease was mainly due to a shift in sales mix with higher weight of generic advisory. Opex increased slightly (+4%) to Euro 2.0 m (Euro 1.9 m in 1H22) as a result of an increase nondeductible VAT, and G&As (+8%) from higher spending on consultancy and training of commercial network. Net result was negative of Euro 0.2 m (Euro 0.6 m in FY21). On the balance sheet we note an increase in Net Equity to Euro 2.8 m (Euro 2.2 m in FY22) following the capital increase concluded in in Q123 with total cash in of Euro 0.8 m, (76% of total amount approved) and partially offset by the net loss of the period considered (Euro 0.2 m vs Euro 0.6 in 1H22). Assets under control came in at Euro 913 m, +8% or Euro 65 m vs. YE22 (Euro 848 m) with total capital collected in 1H23 of Euro 38 m. However, not considering the clousuer of some of inactive contracts, the Company collected just over Euro 133 m, mainly related to the consultancy line (Euro +103 m). Management highlighted that the cleanup of non-active contracts in the portfolio has largely been concluded.

Strengthening of commercial network and new partnerships to support mid-term growth. Management did not provide guidance for FY23 but confirmed commitment to the strategic plan approved in February. In line with the plan, the Company has in the first six months of the year continued to focus on the strengthening of commercial network and new partnerships to further enhance the product portfolio. This has resulted in a partnership with Sara Vita for the development of new products, a partnership with AATech for the development of an innovative technological tool able to map clients' preferences, and more recently, an agreement with an insurance broker for the recruiting of new consultants thanks to which the Company has already been able to add 65 new consultants to its distribution network, bringing the total number to over 100 (35 at year end 2022). This could, in our view, potentially boost insurance revenues already in 2H23. Given all the above and considering 1H23 results we believe that Management has given the grounds for healthy growth in the mid-term, and we hence confirm our positive stance on the stock.

Estimates slightly revised, new target price at Euro 6.51 p.s., potential upside of 156%. With 1H23 largely confirming our expectations for the year, we only made some fine-tuning to our estimates while adding FY25 to our explicit forecast. Prudentially, we did not raise our Fee Income forecast to factor in the stronger sales network, as we wait to see the return of the newly hired consultants in in 2H23. This could however represent an upside to our estimates. We updated our DCF and multiple based target price to Euro 6.51 p.s., (Euro 6.42 p.s.) providing for an upside of 156%. At our target price the stock would be trading at 2023-2024E Equity Value/AuM multiples of 1.53% and 1.46% respectively, vs. peers' average 2.75% and 2.59% and current stock price at 0.68% and 0.65%.







# KEY FINANCIALS

Euro m	2018A	2019A	2020A	2021A	2022A	2023E	2024E	2025E
Assets under Control (AuC)	846	772	924	959	849	949	999	1.049
Profit & Loss Statement								
Fee income	6,4	6,9	5,5	6,3	6,2	7,4	8,9	10,7
Fees expenses	(3,3)	(3,1)	(2,3)	(2,4)	(2,6)	(3,1)	(3,7)	(4,5)
Net fees	3,0	3,9	3,2	3,9	3,7	4,3	5,2	6,2
Brokerage margin Operating costs	3,0 (4,5)	3,8 (3,7)	3,2 (3,3)	3,9 (3,8)	3,6 (4,0)	4,3 (4,0)	5,2 (4,2)	6,2 (4,5)
Pre-tax Profit (Loss)	(1,3)	0,1	(0,2)	(0,3)	(0,8)	0,1	0,5	1,4
Taxes	0,3	(0,1)	0,0	(0,0)	0,0	(0,0)	(0,1)	(0,4)
Net Profit (Loss)	(1,1)	0,0	(0,1)	(0,3)	(8,0)	0,1	0,4	1,1
Balance Sheet								
NWC	2,4 0,2	1,8	2,6	2,4	1,9	2,2	2,4	2,8
Fixed assets M/L Funds	0,2	0,7 0,1	0,7 0,2	1,2 0,2	1,0 0,2	1,0 0,2	1,0 0,2	1,0 0,2
Net Capital Employed	2,4	2,4	3,1	3,4	2,7	3,1	3,3	3,6
Net financial Debt (Cash)	(0,4)	(1,0)	(0,2)	0,5	0,5	0,8	0,5	(0,3)
Total Equity	2,9	3,4	3,3	3,0	2,2	2,3	2,8	3,9
Cash Flow								
Net Profit (Loss)	(1,1)	0,0	(0,1)	(0,3)	(8,0)	0,1	0,4	1,1
D&A Change in M/L Funds	0,1 0,0	0,3 (0,0)	0,3 0,0	0,3 0,0	0,3 (0,0)	0,2 0,0	0,3 0,0	0,3
Gross Cash Flow	(1,0)	0,3	0,0	0,0	(0,0)	0,0	0,0	1,4
Change in NWC	(0,1)	0,7	(0,8)	0,2	0,5	(0,3)	(0,2)	(0,4)
Operating Cash Flow	(1,0)	1,0	(0,6)	0,2	(0,0)	0,0	0,6	1,0
Capex	(0,1)	(0,9)	(0,2)	(0,9)	(0,1)	(0,3)	(0,3)	(0,3)
Free Cash Flow Dividends	(1,1) 0,0	0,1 0,0	(8,0) 0,0	(0,7) 0,0	(0,1) 0,0	(0,2) 0,0	0,3 0,0	0,7 0,0
Change in Equity	0,2	0,5	(0,0)	(0,0)	0,0	0,0	0,0	0,0
Change in Net Debt (Cash)	(1,0)	0,6	(0,8)	(0,7)	(0,1)	(0,2)	0,3	0,7
Per Share Data								
Current Price	€ 2,54							
Total outstanding shares (m)	2,23	2,01	2,01	2,01	2,01	2,23	2,23	2,23
EPS DPS	(0,52) 0,00	0,01 0,00	(0,07) 0,00	(0,13) 0,00	(0,40) 0,00	0,05 0,00	0,20 0,00	0,48 0,00
FCF	(0,50)	0,04	(0,42)	(0,33)	(0,04)	(0,11)	0,13	0,33
Pay-out ratio	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
Ratios								
Fee income/AuM	0,8%	0,9%	0,6%	0,7%	0,7%	0,8%	0,9%	1,0%
Fees expenses/Fee income	-52,4%	-44,0%	-42,0%	-38,6%	-41,0%	-42,0%	-42,0%	-42,0%
Net fees/AuM Brokerage Margin/Fee Inc.	0,4% 47,4%	0,5% 55,5%	0,3% 57,5%	0,4% 60,8%	0,4% 58,3%	0,5% 58,0%	0,5% 58,0%	0,6% 58,0%
Cost/Income ratio	-149,3%	-96,5%	-103,6%	-97,5%	-110,5%	-92,0%	-82,0%	-72,0%
EBT/Brokerage margin	-43,2%	2,1%	-5,0%	-6,9%	-22,1%	3,3%	10,2%	23,2%
Net Debt/Equity	-15,2%	-30,8%	-6,2%	16,2%	23,9%	32,9%	17,6%	-6,5%
Total Equity/Total Assets ROE	70,2% -36,8%	68,4%	63,4% -4,3%	57,2% -9,1%	42,6% -35,9%	48,9%	51,9%	59,5%
Free Cash Flow Yield	-36,6 <i>%</i> -15,1%	0,4% 1,3%	-4,3% -12,7%	-7,1 <i>%</i> -10,0%	-33,7 <i>%</i> -1,3%	5,2% -3,3%	16,1% 3,8%	27,8% 10,0%
Growth Rates								
Assets under Control (AuC)	-22%	-9%	20%	4%	-11%	12%	5%	5%
Fee income	-20%	9%	-20%	15%	-2%	19%	20%	20%
Fees expenses	-14%	-8%	-24%	5%	4%	22%	20%	20%
Net fees	-25%	28%	-17%	21%	-6%	17%	20%	20%
Brokerage margin Pre-tax Profit (Loss)	-27% -378%	27% 106%	-17% -297%	21% -66%	-6% -202%	18% 118%	20% 267%	20% 171%
Net Profit (Loss)	-234%	101%	-1027%	-92%	-195%	115%	267%	139%



2



### **Breakdown Assets Under Control**

Asset Under Control m	1H23	1H22	1H21	1H20	FY 2022	FY 2021	FY 2020
Asset management	246	196	174	172	211	207	160
Advisory	263	246	347	475	252	365	389
Insurance portfolio	371	364	358	298	357	363	356
SICAV	33	28	20	18	29	24	18
Total	913	835	900	964	848	954	924

PMI Capital Research elaboration on Company data

### Breakdown Fee Income

Fee Income	1H23	1H22	1H21	1H20	FY22	FY21	FY20
Asset mgmt. rec.	1,089	941	841	806	1,879	1,756	1,525
Advisory recurring	488	456	433	58	1,080	929	1,548
Performance	77	-	1,036	13	12	1,992	641
Advisory generic	1,583	227	140	142	1,304	767	2,076
Insurance	372	910	634	479	1,953	1,194	662
Other	-	12	-	-	-	-	922
Total	3,608	2,546	3,083	1,998	6,228	6,340	5,529

PMI Capital Research elaboration on Company data

# **Key Financials**

Income Statement – Euro m	1H23A	1H22A	1H21A	1H20A	FY22A	FY21A	FY20A
AuC	913	835	900	964	848	959	924
Fee income	3,6	2.5	3.1	2.0	6.2	6.3	5.5
Fee income /AuC	0,40%	0.30%	0.34%	0.21%	0.71%	0.66%	0.60%
Fee expenses	1,7	1.1	1.1	0.9	2.6	2.4	2.3
Fee expenses / Fee income	46,6%	41.9%	37.1%	42.8%	41.0%	38.6%	42.0%
Net Fees	1,9	1.5	1.9	1.1	3.7	3.9	3.2
Net Fees/AuC	0,21%	0.18%	0.22%	0.12%	0.42%	0.41%	0.35%
Brokerage margin	1,9	1.5	1.9	1.1	3.6	3.9	3.2
Brokerage mgn. / Fee Inc	52,8%	57.1%	62.4%	56.4%	58.3%	60.8%	57.5%
Operating Costs	2.0	1.9	1.9	1.5	(4.0)	(3.8)	(3.2)
Opex/Income ratio	104,7%	125.8%	96.7%	132.6%	110.5%	97.6%	103.6%
Pre-tax Profit / (Loss)	(0.2)	(0.6)	(0.1)	(0.5)	(0.8)	(0.3)	(0.2)
EBT/Brokerage margin	-12,7%	-39.7%	-5.8%	-44.8%	-22.1%	-6.9%	-5.0%
Net Profit / (Loss)	(0.2)	(0.6)	(0.1)	(0.5)	(0.8)	(0.3)	(0.1)

Balance Sheet – Euro m	1H23A	1H22A	1H21A	1H20A	FY22A	FY21A	FY20A
Net Working Capital	2.1	2.0	1.9	1.5	1.9	2.4	2.6
Fixed net assets	0.8	1.1	0.6	0.7	1.0	1.2	0.7
Funds	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)
Net Capital Employed	2.7	2.9	2.3	2.0	2.7	3.5	3.1
Net Debt/(Cash)	(0.1)	0.5	(0.9)	(0.9)	0.5	0.5	(0.2)
Total Equity	2.8	2.4	3.1	2.9	2.2	3.0	3.3
Sources	2.7	2.9	2.3	2.0	2.7	3.5	3.1

Source: Company data (IAS/IFRS)





### **Estimate Review**

Income Statement	2023E	2023E	2024A	2024E	2025E
Euro m	Old	New	Old	New	New
Fee income	7,4	7,4	8,9	8,9	10,7
YoY	19,0%	19,0%	20,0%	20,0%	20,0%
Fee expenses	3,1	3,1	3,7	3,7	4,5
Net Fees	4,3	4,3	5,2	5,2	6,2
YoY	16,9%	16,9%	20,0%	20,0%	20,0%
Brokerage margin	4,3	4,3	5,2	5,2	6,2
Brokerage margin / Fee income	58,0%	58,0%	58,0%	58,0%	58,0%
Operating costs	(4,0)	(4,0)	(4,2)	(4,2)	(4,5)
Cost/Income ratio	-92,0%	-92,0%	-82,0%	-82,0%	-72,0%
Pre-tax Profit / (Loss)	0,1	0,1	0,5	0,5	1,4
EBT/Brokerage margin	3,3%	3,3%	10,2%	10,2%	23,2%
Net Profit / (Loss)	0,1	0,1	0,4	0,4	1,1
EPS (Euro)	0,06	0,05	0,22	0,20	0,48

Balance Sheet	2023E	2023E	2024E	2024E	2025E
Euro m	Old	New	Old	New	New
Net Working Capital (NWC)	2,2	2,2	2,4	2,4	2,8
Fixed net assets	1,0	1,0	1,0	1,0	1,0
Funds	(0,2)	(0,2)	(0,2)	(0,2)	(0,2)
Net Capital Employed	3,1	3,1	3,3	3,3	3,6
Net Financial Position (Cash)	8,0	0,8	0,5	0,5	(0,3)
Total Equity	2,3	2,3	2,8	2,8	3,9
Sources	3,1	3,1	3,3	3,3	3,6

Source: PMI Capital Research estimates

### **Valuation**

We set a target price of 6.51 Eu per share (Euro 6.52 pr.) obtained by weighting equally a Discounted Cash Flow (DCF) model and market multiples and providing for an upside of 156% on current stock price. At our target price the stock would be trading at 2023-2024E Equity Value/AuM multiples of 1.53% and 1.46% respectively, vs. peers' average 2.75% and 2.59% and current stock price at 0.68% and 0.65%.

### **Valuation Summary**

Method	Weight	Price (Eu p.s.)	Equity Value (Eu m)
DCF (Ke 8.42% and g 1.0%)	50%	5.48	12.2
Multiple analysis Market Cap/AuM 23/24 (@ 30% discount)	50%	7.55	16.9
Target Price	100%	6.51	14.6

### **DCF Model**

DCF Valuation		
Sum of PV 2023-29 FCFs Eu m	3.7	30%
Discounted terminal value Eu m	8.6	70%
Equity Value Eu m	12.2	100%
N. of outstanding shares (m)	2.234	
Equity Value (Eu p.s.)	5.48	





### **Market Multiples**

	Country	<b>Market Cap</b> (Euro m)	<b>AuM 22E</b> (Euro m)	Market Cap AuM23E	Market Cap AuM24E
ANIMA Holding SpA	Italy	1.269	189.452	0,7%	0,7%
Azimut Holding SpA	Italy	2.738	75.741	4,1%	3,8%
Banca Generali SpA	Italy	3.355	65.034	6,6%	6,1%
Banca Mediolanum SpA	Italy	5.990	105.054	6,5%	6,1%
Ashmore Group Plc	UK	1.903	56.892	3,0%	2,9%
Janus Henderson Group PLC	UK	3.936	287.937	1,3%	1,3%
Julius Baer Gruppe AG	Switzerland	13.374	475.241	2,8%	2,6%
Jupiter Fund Management Plc	UK	815	63.029	1,0%	1,0%
Liontrust Asset Management PLC	UK	770	45.724	1,4%	1,3%
Man Group Plc	UK	3.291	157.987	2,0%	1,8%
Schroders Plc	UK	8.002	873.980	1,0%	0,9%
St. James's Place Plc	UK	7.256	210.952	2,8%	2,6%
Average		4.060	206.442	2,75%	2,59%
SCM SIM	Italy	7.6	849	0,68%	0,65%

Source: FactSet data as of September 29th, 2023 for peers and PMI Capital Research estimates for SCM SIM

**SCM SIM IN BRIEF** 





#### **COMPANY PORIFILE**

Solutions Capital Management SIM is a Private Banking and Wealth Management company authorized to manage portfolios, provide investment advice and placement services. SCM SIM, founded in 2009 by Antonello Sanna (current CEO), was the first SIM to be listed on the Italian stock market (2016). The Company offers customised advisory solutions, applying a unique, innovative and sustainable business model in Italy, which is based on independence, transparency and the absence of conflicts of interest, in line with the "fee only" advice model. The company offers highly customised investment solutions with several lines depending on the customer's risk profile as well as wealth planning and wealth management services.

#### **STRATEGY**

The strategy of SCM Sim for 2023-2025, as outlined in the Business Plan, focuses on the following goals:

- strengthening of the commercial network with the entry of new resources,
- develop partnerships with insurance brokers
- development of the corporate division
- sustainable growth of AuC
- increase customer base
- expand commercial offer

#### MANAGEMENT

Antonello Sanna – CEO
Maria Leddi - Chairman
Roberto Santoro – Board
Member
Francesco Barbato – Board
Member
Antonio Somma –
Independent Board
Member
Massimo Nicolazzi – Board
Member
Eugenio Tornaghi –
Independent Board

#### **KEY SHAREHOLDERS**

Member

HPS Holding 79.44% Market 20.56%

#### **SCM SIM IN CHARTS**



#### MAIN OPPORTUNITIES

- Unique business model based on Independence, Transparency and No conflict of interests in line with UK best practice.
- MiFID II compliant: since its authorization in 2010, SCM SIM has adopted a business model that "No rebates" (the Company does not receive fees from issuers, but only from customers).
- Management team with long experience in the financial industry.
- Skilled team of financial and insurance consultants. New partnership for recruitment.

### **MAIN RISKS**

- Dependence on financial market performance.
- Regulatory environment. The Company operates in a highly regulated market, where its products are strongly impacted by changes in the current legislation.
- Reputational risk by customers, shareholders, investors or Supervisory Authorities (e.g. privacy violation).
- Low free float and stock liquidity.

SCM SIM ON EURONEXT GROWHT MILAN

PMI CAPITAL



#### IPO

Trading Market: Euronext Growth Milan

Date: July 28<sup>th</sup>, 2016 Price: Euro 10.59

Capital raised: Euro 2.2 m Capitalisation: Euro 20.2 m

### **SHARES** (as of September 29<sup>th</sup>, 2023)

Code: SCM

Bloomberg: SCM IM Reuters: SCM.MI ISIN: IT0005200248 Shares: 2,006,240

Share capital: Euro 2,234,264

Price: Euro 3.3 p.s.

Performance from IPO: - 76% Capitalisation: Euro 6 m Free Float: 20.39% NomAd: MIT Sim


#### STOCK OPTION PLAN

The Shareholders have approved a share capital increase of a maximum of no. 400,000 new ordinary shares for the stock option plan in place. Subject to certain conditions the beneficiaries (employees with strategic roles, members of the Board of Directors and financial advisors) will be able to exercise the option right and subscribe for the shares at a price of Euro 4.15.

### **OWNERSHIP**

Shareholder	N° of shares	%
HPS Holding Partecipazioni Societarie Srl	1.778.800	79.61%
Market	455.464	20.39%
Total	2.234.264	100,000%

### STOCK PERFORMANCE







#### DISCLAIMER

UPDATES: This Research is an update coverage made by IR Top Consulting S.r.l. (IR Top) on SCM SIM (the "Company"). Update frequency might depend on circumstances considered to be important (corporate events and changes of recommendation, etc.) or on further advisory commitment. Last Research on the same Company was released on March 27th, 2023. Opinions and estimates of this Research are as the date of this material and are subject to change. Information and opinions have been obtained from sources public and believed to be reliable, but no warranty is made as to their accuracy or correctness. Past performances of the Company are not guarantee of future results. During the last 12 months, the following indications have been disseminated:

Date	Target Price	Market Price	Validity Time
October 2 <sup>nd</sup> , 2023	6.51	2.54	12 months
March 27 <sup>th</sup> , 2023	6.42	3.32	12 months
October 4th ,2022	6.52	3.60	12 months
April, 19th, 2022	7.63	3.96	12 months
October 13th, 2021	6.66	4.00	12 months
May 4 <sup>th</sup> , 2021	6.61	4.04	12 months
October 20th, 2020	6.96	4.12	12 months
May 13 <sup>th</sup> , 2020	7.32	4.98	12 months
November 7th, 2019	7.24	4.10	12 months
May 15 <sup>th</sup> , 2019	7.15	4.74	12 months
October 25th, 2018	9.25	8.50	12 months
June 7th, 2018	10.24	9.20	12 months

VALUATION METHODOLOGY (HORIZON: 12M): IR Top obtained a fair value using different valuation methodologies including Discounted Cash Flow method and Multiple-based models. Detailed information about the valuation or methodology and the underlying assumptions and information about the proprietary model used is accessible at IR Top premises.

#### RESEARCH TEAM

Luisa Primi, (Senior Analyst, AIAF Associated)

No other people or companies participated or anyhow contributed to the Research. Neither the members of the research team, nor any person closely associated with them have any relationships or are involved in circumstances that may reasonably be expected to impair the objectivity of the Research, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them, who was involved in producing the Research.

INTERESTS INVOLVED AND CONFLICTS: This document has been prepared by IR Top, on behalf of the Company according to a contract, under which IR Top undertook to prepare this report expressing only independent, fair and balanced views on the Company. The fees agreed for this Research do not depend on the results of the Research.

This Research has been disclosed to the issuer to which the Research, directly or indirectly, relates before its release. It is incumbent on the Company to provide timely and constructive feedback on draft Research prior to publication. It is IR Top's sole discretion as to whether comment and feedback from the Company is incorporated into the Research prior to publication and where it is, a further iteration to the draft will be sent to the Company for comment.

IR Top is also engaged in investor relations services in the interest of the Company and might occasionally be involved in other consulting activities intended to increase the value of the Company. In any case, Chinese Walls and other information barriers are in place to avoid the exchange of confidential information between the Equity Research Department and other services areas; employees and advisors involved in such services have restrictions preventing them from the access to confidential information that cannot be published.

IR Top restricts research analysis from performing roles, which could prejudice the independence of their research. In particular:

- they are permitted to attend and speak at widely attended conferences or other widely attended events at which IR Top colleagues and clients, among others, may also be present, provided that their independence may not be affected. These widely-attended conferences/events may include some investor presentations by clients of investor relations services.
- Analysts are also permitted to attend and speak at conference calls or meetings between analysts and bankers, investors or customers in which are discussed Research reports already published or general view on specific sectors. In such cases, at the start of that meeting, bankers, investors or customers need to be clarified that the discussion cannot involve the communication of privileged information to the analyst as the analyst would be prohibited from producing new research report on the companies whose privileged information has been disclosed.

Members of the Research Team do not receive salaries, commissions, bonuses or any other form of compensation based upon specific investment banking transactions or securities' performances

IR Top and the members of the Research Team do not have any further interest or conflict of interest directly or indirectly related with the Research, the Company or the securities, that may reasonably be expected to impair the objectivity of the Research.

There are no other interests or conflicts of interest of any person belonging to the same group of IR Top that are: (a) known, or reasonably expected to be known, to the persons involved in the production of the recommendation; or (b) known to persons who, although not involved in the production of the recommendation, have or could reasonably be expected to have, access to the recommendation prior to its completion.

In any case, as a general Policy, nobody of the Research Team nor IR Top is allowed to have a financial interest in the securities of the client company or serve as an officer, director or advisory board member of the client company.

Analysts must not undertake personal transactions on financial instruments that are object of the investment research or that relate to the same industry. Exceptions may be made with the prior approval of IR Top's CEO in special circumstances such as for disposal of (a) positions already held before the employment or before the implementation of the company policy, or when initiating coverage and (b) positions obtained as a result of the issuer extraordinary activities. By the way, when analysts hold instruments to which Equity Research relates, they are required to disclose their interests in Research reports. Any trades that analysts make must be in line with their recommendation(s), contained in the last published Research. An analyst is prohibited from producing a Research on an issuer if the analyst carries out activities for which he receives compensation from the issuer. If an analyst's household member / relative / relative in-law (within the second degree) serves in such a high capacity for the issuer (i.e. manager or director), the analyst has to inform IR Top's CEO and the analyst will cease covering the issuer.

**POLICY:** IR Top has in place a "Joint conflict management policy" in order to effectively manage any conflicts of interest, and an "Equity Research Policy", in order to rule research services in compliance with Parliament Regulation (EU) no.596/2014 and Commission Delegated Regulation (EU) no. 958/2016 on Market Abuse.

IR Top has adopted the "Joint conflict management policy" in accordance with best practice regarding "information barriers" to restrict the flow of information to prevent the misuse of information and/or prevent any conflicts of interest arising from other activities of IR Top. A copy of these policies is available to the recipient of this Research upon making a request to IR Top by e-mail.

DISCLAIMER: This report has been prepared solely for information purpose and is not intended as an offer or solicitation with respect to the purchase or sale of any financial products. It should not be regarded as a substitute for the exercise of the recipient's own judgment. IR Top does not accept any liability for any direct, consequential or indirect loss arising from any use of material contained in this report. This document may only be reproduced or published together with the name of IR Top. Opinions and estimates in this Research are as at the date of release and are subject to change without notice to the recipient. Information and opinions have been obtained from sources believed to be reliable, but no representation or warranty is made as to their accuracy or correctness. Past performance is not a guarantee of future results. The investments and strategies discussed in this Research may not be suitable for all investors. In any case, you should consult your investment advisor.

This document is intended for distribution only to E.U. "qualified investors" and to "qualified counterparties" resident in Italy, within the meaning of article 2(1)(e) of the prospectus directive (directive 2003/71/EC) and Consob Reg. 16190, as subsequently amended and supplemented; its distribution in USA, Canada, Australia, Japan is not allowed. In Italy, this document is being distributed only to, and is directed at qualified investors within the meaning of article 100 of legislative decree no. 58 of 24 February 1998, as amended,

In Italy, this document is being distributed only to, and is directed at qualified investors within the meaning of article 100 of legislative decree no. 58 of 24 February 1998, as amended, and article 34-ter, paragraph 1, letter b), of Consob regulation on issuers no. 11971 of May 14, 1999, provided that such qualified investors will act in their capacity and not as depositaries or nominees for other shareholders, such as persons authorized and regulated to operate in financial markets, both Italian and foreign.

**DISTRIBUTION:** In the United Kingdom, this document is not for distribution to persons that would be defined as private customers under rules of the FSA; it is for distribution only to persons who: (i) have professional experience in matters relating to investments falling within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (as amended, the "financial promotion order"), (ii) are persons falling within article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the financial promotion order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FINANCIAL SERVICES AND MARKETS ACT 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons").

This document is not addressed to any member of the general public and under no circumstances should this document circulate among, or be distributed to (i) a member of the general public, (ii) individuals or entities falling outside the definition of "qualified investors" as specified above or (iii) distribution channels through which information is or is likely to become available to a large number of persons.

IR TOP CONSULTING SPECIFIC DISCLOSURES: We disclose that IR Top acts as Investor Relations and Financial Communication advisor for the Company.



SCM